BACKGROUND AND OBJECTIVES: To improve the survival rate of patients with colon cancer, liver metastases must be eradicated in a clinically occult state. This study was designed to find a predictor for potential liver metastases or micrometastases in colon cancer. METHODS: Peripheral blood samples and tumor specimens were obtained from 36 patients with colon cancers. The blood samples were subjected to reverse transcriptase-polymerase chain reaction (RT-PCR) analysis, and the expression of sialylated carbohydrates was also investigated in the tumors immunohistochemically. RESULTS: A carcinoembryonic antigen (CEA)-specific signal in the blood was detected in 9 of 12 (75%) patients with liver metastasis and in 8 of 24 (33%) patients without liver metastasis, respectively (P < 0.05). The positive rates of sialyl Lewis A (sLeA) and sialyl Lewis X (sLeX) were 36.3% and 40% in tumors without liver metastasis vs. 58.3% and 100% with liver metastasis, respectively. Within a year after surgery, liver metastases became clinically evident in three of the four patients without liver metastasis who showed a CEA-positive signal in their blood preoperatively and who had tumors with a strong expression of sLeX. CONCLUSIONS: A combination of both markers may provide prognostic information for liver metastases in colon cancer. Copyright 2000 Wiley-Liss, Inc.
BACKGROUND AND OBJECTIVES: To improve the survival rate of patients with colon cancer, liver metastases must be eradicated in a clinically occult state. This study was designed to find a predictor for potential liver metastases or micrometastases in colon cancer. METHODS: Peripheral blood samples and tumor specimens were obtained from 36 patients with colon cancers. The blood samples were subjected to reverse transcriptase-polymerase chain reaction (RT-PCR) analysis, and the expression of sialylated carbohydrates was also investigated in the tumors immunohistochemically. RESULTS: A carcinoembryonic antigen (CEA)-specific signal in the blood was detected in 9 of 12 (75%) patients with liver metastasis and in 8 of 24 (33%) patients without liver metastasis, respectively (P < 0.05). The positive rates of sialyl Lewis A (sLeA) and sialyl Lewis X (sLeX) were 36.3% and 40% in tumors without liver metastasis vs. 58.3% and 100% with liver metastasis, respectively. Within a year after surgery, liver metastases became clinically evident in three of the four patients without liver metastasis who showed a CEA-positive signal in their blood preoperatively and who had tumors with a strong expression of sLeX. CONCLUSIONS: A combination of both markers may provide prognostic information for liver metastases in colon cancer. Copyright 2000 Wiley-Liss, Inc.
Authors: H F Loponte; I A Oliveira; B C Rodrigues; R Nunes-da-Fonseca; R Mohana-Borges; F Alisson-Silva; W B Dias; A R Todeschini Journal: Glycoconj J Date: 2022-04-05 Impact factor: 3.009
Authors: Horst Schuldes; Daniel Schleicher; Gottfried Mayer; Bernd H Markus; Jindrich Cinatl; Roman A Blaheta Journal: Int J Colorectal Dis Date: 2003-02-01 Impact factor: 2.571
Authors: Catarina Gomes; Hugo Osório; Marta Teixeira Pinto; Diana Campos; Maria José Oliveira; Celso A Reis Journal: PLoS One Date: 2013-06-14 Impact factor: 3.240
Authors: Fania S Doekhie; Hans Morreau; Geertruida H de Bock; Frank M Speetjens; N Geeske Dekker-Ensink; Hein Putter; Cornelis J H van de Velde; Rob A E M Tollenaar; Peter J K Kuppen Journal: Cancer Microenviron Date: 2008-08-06
Authors: Raoul A Droeser; Christian Hirt; Serenella Eppenberger-Castori; Inti Zlobec; Carsten T Viehl; Daniel M Frey; Christian A Nebiker; Raffaele Rosso; Markus Zuber; Francesca Amicarella; Giandomenica Iezzi; Giuseppe Sconocchia; Michael Heberer; Alessandro Lugli; Luigi Tornillo; Daniel Oertli; Luigi Terracciano; Giulio C Spagnoli Journal: PLoS One Date: 2013-05-29 Impact factor: 3.240